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Background: Thoracic epidural analgesia (TEA) is recommended for post-operative pain relief in patients undergoing
major abdominal surgery via a midline incision. However, the effectiveness of TEA is variable with high failure rates
reported post-operatively. Common side effects such as low blood pressure and motor block can reduce mobility and
hinder recovery, and a number of rare but serious complications can also occur following their use.
Rectus sheath catheters (RSC) may provide a novel alternative approach to somatic analgesia without the associated
adverse effects of TEA. The aim of this study is to compare the efficacy of both techniques in terms of pain relief,
patient experience, post-operative functional recovery, safety and cost-effectiveness.
Methods/design: This is a single-centre randomised controlled non-blinded trial, which also includes a nested
qualitative study. Over a two-year period, 132 patients undergoing major abdominal surgery via a midline incision will
be randomised to receive either TEA or RSC for post-operative analgesia. The primary outcome measures pain scores
on moving from a supine to a sitting position at 24 hours post wound closure, and the patient experience between
groups evaluated through in-depth interviews. Secondary outcomes include pain scores at rest and on movement at
other time points, opiate consumption, functional recovery, morbidity and cost-effectiveness.
Discussion: This will be the first randomised controlled trial comparing thoracic epidurals to ultrasound-guided rectus
sheath catheters in adults undergoing elective midline laparotomy. The standardised care provided by an Enhanced
Recovery Programme makes this a comparison between two complex pain packages and not simply two analgesic
techniques, in order to ascertain if RSC is a viable alternative to TEA.
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Background and rationale
Enhanced Recovery Programmes (ERP) consist of a se-
ries of protocolised multimodal interventions aimed at
reducing complications, thereby expediting recovery [1].
One of the key elements in all ERP is the provision of
adequate post-operative analgesia. This reduces the stress
response, improves patient wellbeing and allows early mo-
bilisation. Early mobilisation itself is important to reduce
secondary complications such as chest infection and deep
vein thrombosis. Post-operative insulin resistance, which
has been linked to increased complications, can be re-
duced by muscle activity [1]. Thoracic epidural analgesia
(TEA), which facilitates dynamic analgesia and early mo-
bilisation, is currently the standard for post-operative an-
algesia following major abdominal surgery within ERP [1].
A number of systematic reviews and meta-analyses have
demonstrated that TEA is associated with superior post-
operative analgesia and fewer adverse events when com-
pared to high dose systemic opiate administration [2-8].
High dose systemic opiates are strongly associated with
post-operative sedation, ileus [8-11] and nausea and vo-
miting, all of which impair post-operative recovery and
prolong hospital stay. Ileus is the most common complica-
tion following abdominal surgery, and is responsible for
significant prolongation of recovery times. TEA may re-
duce ileus rates as compared to opiates [12-17].
TEA is occasionally contraindicated and may also lead
to rare but significant complications, for example nerve
injury, epidural haematoma and epidural abscess [18].
More common adverse effects of TEA include motor
blockade of the lower limbs and urinary retention re-
quiring catheterisation, both of which can impede post-
operative mobilisation and recovery. Additionally, the
need to use epidural opioids to prevent the sensory regres-
sion associated with the use of local anaesthetics alone
may contribute in itself to an increase in post-operative
ileus [13-15]. Hypotension, resulting from sympathetic
nervous blockade, is common with TEA and may result in
iatrogenic fluid overload [19]. Fluid overload is also associ-
ated with ileus and other post-operative complications, in-
cluding anastomotic dehiscence, and has been shown to
independently predict increased length of hospital stay
[20]. TEA has also been found to have a high reported fail-
ure rate (25 to 30%) [2-8]. These failures are multifactorial
and usually managed either by epidural replacement, sub-
stitution with systemic opiate infusion or both [21,22].
Rectus sheath catheters (RSC) are a regional anaes-
thetic technique in which the ventral rami of the seventh
to twelfth intercostal nerves, which supply the rectus ab-
dominis muscle and overlying skin, are blocked [23,24].
This provides midline somatic analgesia, with additional
doses of systemic opiate required for visceral analgesia
(12 to 36 hours duration) [23,24]. This sensory blockadeis achieved by injecting local anaesthetic into the poten-
tial space between the rectus muscle and the posterior
rectus sheath. As a single bolus of local anaesthetic has a
maximum duration of 12 hours [23,24] it is necessary to
insert a catheter into this space to allow either a conti-
nuous infusion of local anaesthetic, or repeated boluses
of local anaesthetic every 8 to 12 hours for 48 to 72
hours post-operatively. Although this regional block was
first described at the turn of the last century [23,24], it
was used infrequently until the recent availability of
long-acting local anaesthetic agents, small portable ultra-
sound machines [25] and small calibre infusion catheters.
These developments have resulted in renewed interest in
RSC for the management of post-operative pain following
midline abdominal incisions [23,24,26-29].
RSC offer several potential advantages over TEA, which
may make them ideally suited for use in an ERP. In par-
ticular, they avoid hypotension and motor blockade. RSC
are also inserted after the induction of general anaesthesia,
which patients may prefer to the usual awake insertion of
epidurals. No complications or serious adverse events re-
lated to RSC have been reported to date [23,24], but local
anaesthetic toxicity [30-33] (which applies to all regional
anaesthetic techniques including epidurals) and visceral
injury during insertion are hypothetical possibilities.
The existing literature relating to the use of RSC is
limited, with published studies all utilising surgically
inserted RSC to compare local anaesthetic with saline
[34-40] or non-randomised trials comparing RSC to epi-
durals [38,40]. Despite this, the majority of studies dem-
onstrate proof of concept [34-37,39]. This randomised
controlled trial will compare ultrasound-guided inser-
tion of RSC with TEA for midline laparotomy incisions,
in adults undergoing elective major abdominal surgery
within an ERP pathway.
Objectives
The aim of the study is to assess the efficacy, safety and
acceptability to patients of RSC. To this end, a qualita-
tive study has been nested within the primary study de-
sign to facilitate understanding of the patient experience.
Trial design
This is a randomised parallel group concealed allocation
non-blinded superiority trial with a nested qualitative
study of a subset of patients.
Methods: participants, interventions and
outcomes
Study setting
TERSC is a single-centre trial, which will take place at
the Royal Blackburn Hospital (RBH), a large district ge-
neral hospital in England providing services to a local
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services to a population of 2 million.
Eligibility criteria
All adult (18 or over) patients who are listed for elective
major abdominal surgery via a midline incision, and who
meet all inclusion and exclusion criteria (see Table 1),
will be eligible for recruitment into the trial.
Interventions
Standard general anaesthetic
All patients in the trial will receive a general anaesthetic
as follows: propofol 2 to 4 mg/kg intravenously (IV);
remifentanil 1 mcg/kg or target controlled infusion (effect
site target-Minto model) or fentanyl 1 to 2 mcg/kg IV;
atracurium 0.5 mg/kg or rocuronium 0.5 mg/kg. Anaes-
thesia will be maintained as follows: isoflurane, sevoflur-
ane or desflurane, initially at 1 MAC (minimum alveolar
concentration) then titrated to clinical end points; remi-
fentanil (RSC arm only) 0.1 to 0.5 mcg/kg/min or target
controlled infusion (effect site target-Minto model) ti-
trated to clinical effect; oxygen in air titrated to SaO2 >
95%; and multimodal anti-emesis consisting of ondanse-
tron 4 to 8 mg, dexamethasone 8 mg and cyclizine 50 mg.
Maintenance fluid will consist of Plasma-Lyte B (Baxter,
Compton, Newbury, Berkshire, UK) at 2 to 4 mls/kg/hr,
and goal-directed fluid therapy utilising 250 ml fluidTable 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Patients >18 years of age • Contraindication to epidural
analgesia: for example,
coagulopathy, local infection,
systemic sepsis, severe aortic
stenosis
• Planned major abdominal
surgery including major
colorectal resections,
pancreaticoduodenectomy and
radical cystectomy
• Consent refused for either TEA or
RSC
• Planned open midline surgical
incision
• Non-English speaker
• Included in the ERP • Ano-rectal excision: for example,
pan-proctocolectomy or
abdomino-perineal resection.
• Willing and able to give
consent
• Planned transverse or oblique
incisional approach
• ASA (American Society of
Anesthesiologists) 1 to 3
• Allergy to local anaesthetic drugs or
opiates
• Opiate tolerance
• Pre-existing chronic abdominal pain
• Extensive existing midline
abdominal scarring
Abbreviations: ERP, Enhanced Recovery Programme; RSC, rectus sheath
catheter; TEA, thoracic epidural analgesia.boluses of Plasma-Lyte B until stroke volume is maxi-
mised. This will be guided by either oesophageal Doppler
or Edwards Flotrac (Edwards Lifesciences, Irvin, California,
USA) cardiac output monitoring.Rectus sheath catheters
The RSC will be inserted bilaterally under ultrasound
guidance (see Additional file 1 for description of the
technique) [23-27] by the anaesthetist immediately fol-
lowing induction of a standard general anaesthetic. Only
anaesthetists who have successfully inserted RSC under
the supervision of the chief investigator (CI) will under-
take the insertion of RSC. An aseptic technique will be
used and 20 ml of 0.25% bupivacaine will be injected via
each catheter into the potential space between the rec-
tus muscle and the posterior rectus sheath, 2 to 4 cm ei-
ther side of the midline. The catheters will be tunnelled
subcutaneously to a level above the costal margin.
Approximately 45 minutes before the end of surgery
a 10-mg bolus of IV morphine will be administered to
provide visceral analgesia. A transdermal fentanyl patch
(12 mcg if ≥70 years and/or ≤65 kg and 25 mcg if <70
years and >65 kg; 72-hour duration of action) will be ap-
plied, and if more than 3 hours have passed since the
initial RSC bolus, a further 40 ml of 0.2% ropivacaine
will be administered via an ambITR (Summit Medical
Products Inc, South Sandy, Utah, USA) Preset PCA or
ambITR mini infusion pump (split between the 2 RSC
via a Y-connector). The pumps will be set to deliver bo-
luses of 40 mls 0.2% ropivacaine, with a 4-hour lockout,
each time the bolus button is pressed [30-33]. The bolus
button may be staff- or patient-activated but will be
pressed regularly every 4 hours post-operatively. Each
40 ml bolus takes 24 minutes to deliver; therefore the
total time from the start of one bolus to the start of the
next will be 4 hours and 24 minutes.
If breakthrough pain is experienced, staff will first en-
sure that the RSC have been utilised as per protocol. If
more than 4 hours have elapsed since the last bolus of
local anaesthetic then 40 mls of 0.2% ropivacaine will
be administered via the pump. If inadequate pain re-
lief follows the bolus, or if no bolus is due, then
10 mg oral morphine or 5 mg oral oxycodone will be
used as required for further breakthrough pain within
the first 48 hours.Thoracic epidural analgesia
Epidurals will be sited prior to the induction of general
anaesthesia at T7 to T9 for a right-sided colonic resec-
tion or upper gastrointestinal (GI) surgery, and T9 to T11
for a left-sided resection or radical cystectomy. Standard
aseptic insertion technique will be followed, using loss of
resistance to air or saline as per preference. Following a
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with 100 mcg fentanyl will be administered to establish a
block.
Following insertion, an epidural infusion of 0.125%
bupivacaine and 2 mcg/ml fentanyl will be commenced
at 10 mls/hour and then titrated to effect. On the second
post-operative night, a fentanyl patch (12 mcg if ≥70 years
and/or ≤65 kg and 25 mcg if <70 years and >65 kg) will be
applied after which the epidural will be weaned overnight
and removed the following morning as per local clinical
protocol.
If breakthrough pain is experienced, the epidural block
will first be optimised with an additional bolus of 10 to
20 mls of the maintenance solution. If inadequate pain
relief follows the bolus then 10 mg oral morphine or
5 mg oral oxycodone will be used as required for further
breakthrough pain within the first 48 hours.
All reasonable attempts will be made to rescue failing
study interventions. These may include delivering an
additional bolus of local anaesthetic, altering the catheter
position, correcting blood pressure to allow continuation
of the study intervention, and (in the case of TEA) repo-
sitioning the patient. However, if complete failure of the
study intervention occurs within the first 48 hours post-
operatively, it will be replaced by IV morphine patient
controlled analgesia (PCA) following an adequate IV bolus
of morphine. Complete failure is defined as complete lack
of any sensory blockade and any improvement in the se-
verity of pain reported by the patient following an ad-
equate bolus injection of local anaesthetic via the TEA
or RSC.
Patients in both arms of the trial will receive all other
hospital care according to our institution’s ERP. Pre-
operatively, this consists of pre-operative assessment,
planning and preparation (including cardiopulmonary
exercise testing if aged ≥60 years or <60 years with car-
diorespiratory comorbidity), ERP information, a patient
diary and PreLoad (Vitaflo International Limited, Liver-
pool, UK) drinks (sachets of maltodextrin powder for re-
constitution in 500 mls water; 2 to be consumed the
night before and an additional one 2 to 3 hours prior to
surgery). Upper GI and right-sided colonic resections re-
ceive no bowel preparation and left-sided colonic re-
sections, rectal resections and radical cystectomies will
receive phosphate enemas on the morning of surgery.
All patients receive 1 g paracetamol and 300 mg gaba-
pentin orally pre-operatively.
Intra-operatively, in addition to the standard general
anaesthetic and interventions already described, nasogas-
tric tubes are avoided, surgical drains minimised and nor-
mothermia is maintained using enFlow® (GE Healthcare,
Little Chalford, Buckinghamshire, UK) IV fluid warmers
and Bair Hugger™ (3 M, St Paul, Minnesota, USA) external
warming blankets.Post-operatively, in addition to the randomised pri-
mary analgesia technique all patients receive multimodal
oral analgesia, comprising 1 g paracetamol 6-hourly orally
or IV if not tolerating oral; 400 mg ibuprofen 8-hourly or-
ally once tolerating full oral diet; and 100 mg gabapentin
8-hourly orally (for 72 hours). A transdermal fentanyl
patch is applied with dose and timing relevant to the ran-
domised intervention as described above. Post-operative
nausea and vomiting is minimised with 3 mg Buccastem
8-hourly buccally for 48 hours. Patients will undergo
structured mobilisation from day 1 post-operatively. IV
fluids are minimised and 2 litres per day of oral fluid is en-
couraged with full oral diet encouraged from day 1 post-
operatively. Urinary catheters will be removed on day 1 in
the RSC group and on removal of the epidural in the TEA
group.
Qualitative study
A cross-sectional study will achieve the aim to study the
patient experience of both interventions. This will util-
ise an inductive approach informed by the principles of
grounded theory [41]. It uses maximum variety sam-
pling to enable a range of experiences to be sought ra-
ther than seeking to make generalisations based on
population characteristics. The anticipated sample size
is 10 per trial arm (20 in total) and interviews will be
undertaken by an experienced researcher at a place con-
venient to the participant (usually their home). During
the qualitative phase all consenting RCT trial partici-
pants will be invited to take part in the qualitative study
RCT (randomised controlled trial). They will be con-
tacted again 2 to 3 weeks after the intervention, invited
to participate and re-consented to avoid any issue of co-
ercion whereby patients feel that they have to consent
to the qualitative study in order to gain entry onto the
RCT.
Face-to-face interviews will then take place 4 weeks
post-intervention. This time point has been chosen to
avoid the initial recovery period after hospital discharge,
whilst still allowing the generation of rich data concern-
ing the experience of RSC or TEA (we expect most pa-
tients to be discharged between 8 and 14 days, and to
require a 3-month leave of absence from work). Data
will be collected through in-depth interviews focusing
on the participant’s expectations, experiences and out-
comes. The interviews will be digitally audio recorded
and fully transcribed (specifically covered in the consent
process). Constant comparative thematic analysis will
be undertaken to detect commonalities and differences
within the accounts and across the two groups. Constant
comparison permits the early stages of analysis to identify
emergent issues and inform later data collection in order
to produce insights grounded in the experiences of the
participants.
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The primary outcome measure of the RCT is the differ-
ence in mean pain score on movement from supine to
sitting position at 24 hours after extubation between
groups, measured using a Visual Analogue Scale (VAS)
of 0 to 100 mm with 0 being no pain and 100 mm being
the worst pain imaginable [42,43]. VAS is a standard tool
to compare analgesic efficacy between interventions in
pain studies, and pain control adequate to allow dynamic
movement at 24 hours is considered key to successful
recovery after major surgery, with full mobilisation thus
potentially feasible. An additional primary outcome mea-
sure is the difference in patient experience measured by
the nested qualitative study utilising interviews conduc-
ted one month after surgery in a subset of patients from
the main trial.
Secondary outcomes include further comparisons of
analgesic efficacy and effectiveness, functional recovery,
safety and cost-effectiveness. Further analgesic quality
measurements include mean VAS pain scores at rest and
on movement at 2, 6, 12, 24, 48 and 72 hours after extu-
bation between intervention groups to compare the effi-
cacy of analgesia at different clinically relevant time
points and the time-based evolution of analgesic efficacy;
the difference in sleep quality measured by VAS scores
on the first three mornings post-operatively; the differ-
ence in self-assessed functional pain categorising respira-
tory function and mobility measured between 4 pm and
5 pm on each of the first 3 post-operative days; time to
first rescue opiate; the total opiate consumption (exclud-
ing the protocolised fentanyl) over the first 48 hours
post-operatively; and an overall score of satisfaction with
pain relief on day 3 post-operatively.
Functional recovery will be compared assessing the
difference in decrement of the Post-operative Quality
Recovery Scale (PQRS) score [44] between groups, from
baseline measurement to the measurements obtained on
days 4, 7 and 30 post-operatively using a validated ques-
tionnaire [44]; time to first mobilisation; the difference
in time to return of GI function; achievement of the
daily ERP mobilisation goals (for example, 4 × 60 m
walks on day 2 post-operatively); adherence to the local
ERP pathway; time until patients meet standardised clin-
ical discharge criteria as per the hospital ERP [45,46];
and the actual length of hospital stay. Return of GI func-
tion is defined as the time to tolerance of full diet, pas-
sage of flatus and bowel opening. Tolerance of a full diet
will occur when the patient has consumed more than
90% of the planned intake of a meal, and does not feel
nauseated or vomit after any meal. If four meals are con-
sumed and the fourth vomited, then time to tolerating a
full meal will not have been reached.
Safety measurements are differences in fluid balance
and the incidence of hypotension over the first 48 hourspost-operatively. Overall fluid balance will be measured
using the fluid balance charts and the difference between
pre-operative body weight and body weight measured on
the first three mornings post-operatively (positive fluid
balance is strongly correlated with morbidity in this co-
hort and may be linked to side effects of the trial interven-
tions, that is hypotension). Any episode of hypotension,
defined as a systolic blood pressure less than 90 mmHg, a
mean arterial pressure less than 65 mmHg, or a reduction
of greater than 20% from the pre-operative blood pressure,
will be noted. Vasoconstrictor usage will be measured as a
surrogate of haemodynamic stability.
Other measures of morbidity include nausea and vo-
miting measured by a VAS score, the incidence of ileus
and the POMS (Post-Operative Morbidity Score). Ileus
has been defined as new nausea and vomiting, abdominal
distension, and abdominal discomfort with loss of bowel
sounds [47]. The POMS is a score of post-operative
morbidity validated in the UK which applies a binary
outcome to each of 9 domains on either day 3, 5 or
7 post-operatively, chosen depending on the type of
surgery [48]. Day 5 will be used for this study. Any
surgical complications occurring within 30 days post-
operatively will be classified for severity using the Clavien-
Dindo classification [49].
If a study intervention is deemed to fail, then the tim-
ing of the failure, any replacement technique and the
reason will be recorded: for example, block failure (pain
and no demonstrable block of abdominal dermatomes);
catheter disconnection; excessive catheter leakage; pre-
mature catheter removal; cessation of infusion due to
hypotension; respiratory depression or possible local an-
aesthetic toxicity (respiratory rate <8/minute or the need
for naloxone, systolic BP <80 or MAP <50; pruritus; cir-
cumoral paraesthesia; seizures; obtundation; arrhythmias;
and cardiovascular collapse).
A full health economic assessment calculating Quality
Adjusted Life Years is beyond the scope of this study.
However, short-term cost-effectiveness will be calculated,
taking into account the cost of consumables, insertion and
management time for the 2 techniques, the respective
length of stay both in hospital and critical care, and read-
missions or re-operations within 30 days of surgery [50].
Participant timelines
When patients are informed of the need for an operation
by their surgical team, verbal agreement will be ascer-
tained for their details to be forwarded to the trial team,
enabling the trial nurse to approach them with verbal
and written information (see Trial Schema, Figure 1). If
willing, a verbal discussion can take place that day, other-
wise patients will be given a copy of the Patient Informa-
tion sheet and then contacted by the trial nurse to discuss
the trial a few days later. Most patients will attend the
Figure 1 Trial schema. Diagram illustrating timelines and patient pathways for both study arms.
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of the decision to operate, and the trial nurse will meet
them there to answer any further questions. If willing to
participate, they will be consented and randomised, fol-
lowing baseline data collection, at that visit. Randomisa-
tion at this point will enable workforce planning for the
day of surgery, as well as participant education on the ERP
and trial data collection. However, some patients may be
initially identified and approached at the POAC stage, and
may therefore be randomised up to and including the day
of admission.
The trial interventions will take place in the anaesthetic
room on the day of surgery, with intensive data collection
up to the third day post-operatively, and further specific
data collection up to 30 days post-operatively.
Sample size
The primary end point is difference in VAS pain scores
on movement at 24 hours post-operatively. The Kelly
study [51] showed that the minimum clinically signifi-
cant VAS pain score when managing severe pain was
10 mm. Standard deviations (SD) varying from 14 mm
to 18 mm have been reported [3-7], thus we have esti-
mated a standard deviation of 18 mm for our study. To
achieve 85% power to detect a 10 mm difference in the
primary end point, from a VAS pain score on movement
at 24 hours of 40 mm (SD =18 mm) in the TEA group,
to 30 mm (SD =18 mm) in the RSC group, at the 5%
level (two-sided t-test), will require 60 patients in each
arm of the study.
An additional 6 subjects will be recruited in each study
arm to cover a maximum of 10% losses (the MASTERSstudy [4] had only 3.5% losses), bringing the total sample
to 132 subjects recruited over 24 months. This sample
size is realistic as we have a recruitment pool of 130 ad-
missions per year and expect 70% to be both eligible and
willing to participate.
Recruitment
Relevant surgical teams, and in particular the specialist
nurses, have been educated on trial eligibility criteria
and will communicate clinic dates for potential partici-
pants to the trial nurse once a decision to operate is
made. Most of these decisions take place at the weekly
Multidisciplinary Cancer Meeting, and the trial nurse
will therefore attend the colorectal meetings.
In addition, all relevant surgical outpatient clinics have
been provided with eligibility posters and trial nurse
contact details as further reminders. POAC personnel
have also received this material, as have the admissions
clerks who are responsible for booking patients into
outpatient and operation dates. This will identify any
additional patients who may have been missed initially.
Clinic dates for benign disease will similarly be commu-
nicated to researchers (this only applies to colorectal
surgery) for all potentially eligible patients.
The trial nurse will then attend the relevant surgical
clinic where patients will be offered major surgery (or
POAC if identified at this stage). Eligible patients will be
asked by the surgical team if they would be willing to be
approached about the study by the research team, or
have their contact details forwarded to the research team.
If they agree, the research nurse will be on hand for an ini-
tial meeting where a verbal explanation of the study will
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Some patients may not feel ready to have a further re-
search related discussion on the same day, but still be
open to the idea of participation. The research nurse will
gain their permission to contact them in a few days to
discuss the study, and they will be provided with the Pa-
tient Information Sheet and contact details. As part of
their surgical pathway, patients will be given an appoint-
ment at the POAC within 2 weeks. The research nurse
will meet them again at this clinic and ascertain if they
wish to participate: if so, they will be randomised, fol-
lowing consent and collection of baseline data. Patients
who are approached for the first time at the POAC may
have this second discussion (± randomization) on the
day of admission, allowing time for consideration.
Only patients with mental capacity and the ability to
consent will be recruited. Patients who are eligible but
not randomised, and those who fulfil the inclusion cri-
teria but meet one or more of the exclusion criteria, will
be recorded in the TERSC Screening Log, irrespective of
whether consent is obtained.
All stakeholders, that is anaesthetists, surgeons and
specialist nurses, will be updated regularly of recruit-
ment to the trial to ensure continued support and en-
couragement with positive feedback. The monthly Trial
Management Group and the 6-monthly Trial Steering
Committee (TSC) will scrutinise the recruitment rate
and provide further suggestions and recommendations
to increase any failing recruitment.
Methods: assignment of interventions
Allocation: sequence generation
Patients will be stratified by operation type and age, with
three surgical strata (radical cystectomies, major colonic
excisions and major rectal excisions) and two age strata
(up to and above forty years of age) by computer gener-
ated random numbers. Of the 66 patients recruited into
each arm of the study, we expect 50% to be major co-
lonic excisions, 30% to be major rectal excisions and
20% to be radical cystectomy cases. Because we expect
to see substantially more patients in the over-40 group, a
2:1 inclusion rate between the age groups is expected. It
should be noted that the radical cystectomy group will
only contain patients over the age of forty, and, there-
fore, in total there will only be five strata. The Trial Stat-
istician has provided the InForm database designers with
lists of the random assignment blocks, without any in-
volvement of the CI or trial nurse.
Allocation: concealment mechanism
The allocation is provided electronically by the InForm
system as described above and is thus concealed to the
research team.Implementation
The trial nurse will enrol patients, and once eligibility
criteria, operation type and demographics are entered,
the InForm system will electronically randomise partici-
pants and assign the interventions.
Blinding
Only the data analysts (trial statistician) will be blinded
to the assigned intervention when assessing the primary
outcome measure.
Methods: data collection, management and
analysis
Data collection methods
The trial research nurse is responsible for recruitment
and data collection and has been trained by the CI. This
training included the correct collection of all trial data
along with definitions of data items and clinical scoring
tools, correct assessment of pain intensity and other VAS
as well as the PQRS score.
Baseline data is obtained in the POAC directly from
the patient and the case notes. All outcome data is either
obtained from the Patient Diaries, case notes, prescrip-
tion, fluid balance and observation charts, or directly by
the research nurse: for example, timing of intervention
insertion, duration of surgery, length of wound, presence
and location of drains and stomas, the use of cardiac
output monitoring to optimise fluid management and
haemodynamic data from monitors.
Patients are educated in the completion of the Patient
Diaries by the research nurse at the pre-operative as-
sessment visit. The research nurse and clinical staff then
prompt patients to self-complete the diaries at specified
time points throughout their stay. These diaries capture
the outcome measures regarding pain control, nausea,
sleep quality, gut function and fitness for discharge.
There are no paper Case Report Forms and all data
collected by researchers will be entered directly onto a
trial-specific eCRF (electronic Case Report Form) on the
InForm database. This system promotes data quality by
preventing duplicate data entry, generating queries when-
ever data deviates from set ranges, and requiring comple-
tion of mandatory fields as defined by the CI. An audit
trail is generated for any data queries, which must be re-
solved before sign-off of completed data by the CI.
A local Research and Development Department quality
manager will audit the quality of data collection periodic-
ally and the Data Management and Ethics Committee
(DMEC) will forward reports of data quality from InForm
to the TSC. Full data collection will continue for all pa-
tients that deviate from the protocol, and patients who
discontinue in the trial will still be assessed for surgical
complications, hospital length of stay and adverse events
up to 30 days.
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ing risk and for various outcome metrics. Peri-operative
risk will be measured using the ASA (American Society
of Anesthesiologists) score [52], and the Physiologic and
Operative Severity Score for the enUmeration of Mortality
and morbidity (p-POSSUM) score (a validated general
surgical risk prediction score) [53]. Quality of Recovery
will be assessed using the PQRS. This is a rapidly con-
ducted instrument allowing assessment of several aspects
of recovery over time. Physiological, nociceptive, emo-
tional and cognitive domains are assessed, with a baseline
(pre-operative) measurement followed by measurements
over several time points. A feasibility study demonstrated
high face validity with applicability to a wide age range, di-
verse languages, cultures, and physical abilities [44].
Details regarding the research interventions, for exam-
ple, insertion, maintenance, protocol violations, adverse
events, compliance with protocolised adjuvant analgesia
and the ERP pathway, and all additional opiate analgesia
will be obtained from case notes or directly by the re-
search nurse. The hospital electronic administration sys-
tem will be interrogated at 30 days for any readmissions
to hospital, ensuring full capture of any adverse events in
this time. The patients will be contacted at 30 days to ob-
tain a final PQRS recovery score by telephone, and this
will be deemed the endpoint for the primary study. A sub-
set of patients will go on to be interviewed for the nested
qualitative study.
Data management
All patient trial data will be entered directly into the se-
cure web-based InForm database eCRF using a tablet de-
vice. Patient diaries, PQRS paper questionnaires and the
medical notes will serve as source data. The CI will be
responsible for data collection, quality and recording,
however the collection of data will be delegated to the
trial research nurse. This has been recorded in the Dele-
gation of Trial Duties Log and authorised by the CI.
All data entered into the eCRF will be anonymised
with only initials and date of birth entered. A separate
and secure log will be kept with consent forms and iden-
tifiers to allow patient follow-up to 30 days. This is de-
tailed in the Patient Information Sheet and emphasised
on the consent form. During the conduct of the trial, all
electronic patient data will be encrypted and all trial
documents stored securely. On completion of the trial,
all patient data (electronic and paper) and other trial
documents will be archived securely and retained for
5 years at RBH in the case of paper documents and Im-
perial Clinical Trials Unit (CTU) in the case of elec-
tronic data.
Imperial CTU is registered under the Data Protec-
tion Act 1998 and all Imperial CTU staff have under-
gone data protection and International Conference onHarmonisation (ICH) Good Clinical Practice (GCP) train-
ing. The CI and all research staff at the Trial Centre have
undergone GCP training.
The InForm database generates automatic alerts for
missing data, invalid data, data duplication or data not
conforming to the rules established for that data type.
Thus, validation is ongoing throughout the data entry
process. Final data validation occurs at Imperial CTU.
This will ensure all data is complete, accurate and con-
sistent. The trial nurse will resolve data queries gener-
ated by the database as soon as possible.
TERSC will be managed according to the Medical Re-
search Council’s (MRC) Guidelines for Good Research
Practice, Guidelines for Good Clinical Practice (GCP) in
Clinical Trials, and Procedure for Inquiring into Allega-
tions of Scientific Misconduct.
Statistical methods
A full statistical analysis plan will be written, a priori,
before the investigators are unblinded to any trial out-
comes by the trial statistician. All analyses will be per-
formed according to the intention-to-treat principle. An
additional per protocol analysis will be performed and
reasons for any protocol violations reported. Baseline co-
variates will be reported for the two groups and described
using summary statistics. To determine if the two groups
are balanced, standard hypothesis tests (t-test, Mann-
Whitney U-test and Chi-squared test) will be applied.
Prior to writing the statistical analysis plan, we will deter-
mine if the analyses of the primary or secondary outcomes
need to be adjusted for significant clinical or demographic
covariates. However, we will only adjust the analysis if sig-
nificant differences in these covariates exist between the
treatment and control groups. The primary analysis will
test the null hypothesis that there is no difference in
mean VAS pain scores on movement at 24 hours post-
operatively between those receiving TEA and RSC anal-
gesia. The independent sample t-test or Mann-Whitney
U-test will be used to assess between group differences
unless the preliminary analysis indicates a significant dif-
ference in the clinical or demographic covariates thought
to have a significant impact on the primary outcome. If so,
then analysis of covariance will be used to assess the pri-
mary outcome. As there are six follow-up measurements,
a repeated measures analysis of variance will also be used
to assess differences between groups, and over time.
The secondary outcomes will be analysed in a similar
manner to the primary outcomes. Time to event varia-
bles, such as time to recovery of gut function and length
of hospital stay will be analysed using Mann-Whitney
U-test, log-rank or Cox regression if censoring occurs.
To avoid missing data we will monitor the data on a regu-
lar basis, monthly, and when possible return to the source
of the missing data to determine if data is available. At
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data and use appropriate imputation methods to estimate
missing values.
Methods: monitoring
Data monitoring
The DMEC will consist of an independent academic
clinician and an independent statistician, and will meet
every 6 months. Operating under the DAMOCLES Char-
ter [54,55], the DMEC will receive reports on recruitment
rates, adverse events, completeness of data collection and
protocol violations, and will report in turn to the TSC.
Harms
Adverse events (AE) and serious adverse events (SAE)
are defined in this trial according to Directive 2001/20/
EC, 4 April 2001, of the European Parliament (Clinical
Trials Directive) and ICH (International Conference on
Harmonisation) GCP E6 guidelines. All AE occurring in
the 30-day follow-up period will be recorded and evalu-
ated for severity and causality. Severity will be graded 1
(mild) through 5 (fatal) and causality will be graded as
either none, unlikely, possible, probable or definitely re-
lated to the intervention. SAE will also be evaluated for
expectedness. SAE will be reported to the Chief Investi-
gator (CI) within 24 hours. The CI will assess all SAE to
determine the need for expedited reporting to the DMEC,
TSC and Research Ethics Committee.
Auditing
The hospital Research and Development Department
quality manager will conduct local monitoring of trial
quality after the first patients have been enrolled. The
trial database provides on-going data quality checking.
The DMEC will look at recruitment rate, data quality
and adverse event reporting and provide a summary re-
port every 6 months.
Ethics and dissemination
Research ethics approval
The Greater Manchester East Research Ethics Commit-
tee granted ethical approval (REC reference: 13/NW/
0782 61767) on the 19 November 2013. Informed pa-
tient consent will be obtained from all participants be-
fore enrolment in the trial.
Protocol amendments
Any significant protocol amendments will be communi-
cated to the Research Ethics Committee and tabulated
along with the amendment date and updated version
number in the protocol. The local research team, the
Trial Management Group, Trial Steering Committee and
the Data Monitoring and Ethics Committees will all be
informed.The National Institute for Health Research (NIHR)
portfolio team and the Controlled Trials Registry where
the trial is registered will also be informed.
Consent
Please refer to the ‘qualitative study’, ‘participant timeline’,
and ‘recruitment’ sections above for details on consent.
Confidentiality
Please refer to the ‘data management’ section above for
details on confidentiality.
Declaration of interests
None.
Access to data
The trial statistician and the DMEC will have access to
the final trial dataset.
End of trial
This will occur when the final patient has completed
their 30-day post-operative follow-up and the final qua-
litative interview has taken place. At this point, all elec-
tronic and paper trial data will be securely archived
for a minimum of 5 years in accordance with ICH GCP
guidelines. Arrangements for confidential destruction of
all documents will then be made. The trial may be stopped
early upon recommendation of either the TSC or DMEC.
If this occurs, all randomised patients will continue to be
followed up as per the trial protocol.
Post-trial care
Due to the short duration of the intervention no post-
trial care is required.
Dissemination policy
Following completion of the trial a report will be pro-
duced for the NIHR who have funded the trial. Several
peer reviewed journal publications will be produced re-
porting various aspects of the trial and results will be
presented at relevant scientific meetings. A lay version
of the results will be available for all trial participants
who request a copy, and for all hospital staff.
Discussion
Epidurals are in routine use in the National Health Service
(NHS) [2,18], and their risks and benefits are well de-
scribed; therefore this study does not confer any additional
risk to trial patients. RSC carry a theoretical risk of needle
damage to viscera on insertion (very unlikely under ultra-
sound guidance) and local anaesthetic toxicity (this applies
to both interventions). However, to date no cases of either
have been reported [23]. Clinical experience suggests good
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is required to provide direct comparison with epidurals.
We considered whether to blind the main study to mi-
nimise any potential bias. Unfortunately, blinding of staff
would be impossible, as they are responsible for admin-
istering the drugs (by very distinct routes, with different
pumps and different settings), as well as monitoring for
adverse events related to the techniques. Single blinding
(patient) was then considered but this was rejected for
two reasons. These were the high likelihood of acciden-
tal unblinding, and the unacceptability of inserting sham
epidurals or RSC. Allocation concealment will avoid selec-
tion bias but observer bias remains a risk. Blinding the
data analyst to the intervention group will ameliorate this.
As we will be studying three different categories of
surgery, with different expected rates of morbidity and
hospital stay (secondary outcome measures), we have
stratified randomisation to account for this and ensure
these categories are balanced. The same applies to age.
The vast majority of cancer cases are older-aged, how-
ever a younger cohort of patients with inflammatory
bowel disease exists, for whom providing pain relief is
notoriously difficult and hospital stays are often longer.
VAS pain scores are a necessary primary outcome
measure for pain studies as they allow quantitative sta-
tistics. They are efficient to collect and easy for patients
to understand, but are recognised as subjective in nature
with individual variation, error in administration and
limited to measuring pain intensity. Therefore, we will
also be comparing a host of other measurements of
quality of analgesia: for example, time to first rescue opi-
ate, the amount of additional opiate, measurements of
functional mobility and breathing, overall satisfaction
with pain relief, measures of recovery and patient experi-
ence with their intervention. Several important second-
ary outcomes will allow further differentiation between
the interventions regarding safety, experience and func-
tional recovery.
There are several unique pragmatic aspects to the stu-
dy design which will help to reduce confounders and
improve the generalisability of results. Firstly, patients
will have all other aspects of care standardised by inclu-
sion in the ERP, with the respective trial interventions
the only difference in processes of care. It is important
to note that the respective trial interventions are not
merely the insertion of an epidural compared to the in-
sertion of a RSC, but rather two overall packages of
analgesia and the way in which the interventions are
managed: for example, the use of transdermal fentanyl
patches in both groups at different appropriate time
points, the universal use of gabapentin and simple an-
algesia, the portable pump system delivering the local
anaesthetic via the RSC, robust protocols to optimise
inadequate epidural or rectus sheath blocks and anybreakthrough pain, and patient education pre-operatively
regarding their allocated intervention, their role in their
recovery and diary completion. A clear protocol states
when an intervention is considered to have failed and the
conversion to rescue analgesia.
Secondly, the use of transdermal fentanyl patches de-
serves further mention. These are used routinely in our
institution as a step down from epidural analgesia. In
order to manage the visceral pain component in the RSC
arm, the patches are applied, following a single dose of
morphine and a further RSC bolus, in the final 45 minutes
of surgery. Visceral pain, although severe, is short-lived (6
to 24 hours) [23] and in our experience is effectively man-
aged with a 12 mcg or 25 mcg patch. Previous studies
have used morphine PCA in addition to the RSC for this
visceral pain. However, there is a danger that the RSC are
not optimised in these cases, with morphine being relied
upon for any breakthrough pain. This would negate the
benefits of a potentially good block, and could result in
the side effects of high dose opiates as previously dis-
cussed. A morphine PCA would also require an additional
pump and would further complicate mobilisation. Instead,
we make use of oral morphine for any opiate required in
addition to the patch.
Aside from increasing the quality of care provided to
all patients participating in this study, further benefits to
our institution include acquisition of new clinical skills
for anaesthetic and ward staff regarding the insertion
and management of RSC, new research skills and devel-
opment of a research ethos for all staff involved, and po-
tential reduction in morbidity and consequently hospital
stay, leading to economic benefit.
Many surgical procedures that have previously been per-
formed via midline incision are now being performed lap-
aroscopically [56] or via transverse incisions. Neither of
these approaches requires the interventions described in
this trial. However, emergency laparotomies will continue
to require an open midline approach. This group has a
mortality rate 5- to 10-fold greater than the elective popu-
lation, comprising in excess of 5,000 cases per year due to
bowel cancer alone in England [56]. These vulnerable pa-
tients are frequently managed with high dose systemic opi-
ate as many have contraindications to epidural analgesia.
Therefore, if RSC demonstrate benefit, the technique may
have widespread application in this surgical cohort.
Trial status
Recruitment began on the 10th February 2014 with
planned completion on the 10th February 2016.
Additional file
Additional file 1: Rectus sheath catheter insertion technique.
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